Novelion Therapeutics Inc. (NVLN) financial statements (2022 and earlier)
Company profile
| Business Address |
C/O NORTON ROSE FULBRIGHT VANCOUVER, BC V6B 0M3 |
| State of Incorp. | BC |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 45,154 | 55,430 | 108,927 | 141,824 | 155,908 | 118,521 | 307,384 | ||
| Cash and cash equivalents | 45,154 | 55,430 | 108,927 | 141,824 | 155,908 | 118,521 | 307,384 | ||
| Restricted cash and investments | 253 | 390 | |||||||
| Receivables | 28,912 | 22,191 | 9,339 | 301 | 410 | 4,590 | 3,960 | ||
| Inventory, net of allowances, customer advances and progress billings | 12,745 | 15,886 | 74,721 | ✕ | ✕ | ||||
| Inventory | 12,745 | 15,886 | 74,721 | ||||||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 1,442 | ||
| Assets held-for-sale | ✕ | ✕ | ✕ | ✕ | ✕ | 300 | |||
| Income taxes receivable | ✕ | ✕ | ✕ | ✕ | ✕ | 77 | 554 | ||
| Other undisclosed current assets | 15,732 | 11,183 | (27,241) | 611 | 1,053 | 38,636 | 49,399 | ||
| Total current assets: | 102,543 | 104,943 | 166,136 | 142,736 | 157,371 | 161,824 | 363,039 | ||
| Noncurrent Assets | |||||||||
| Inventory, Noncurrent | 36,202 | 33,940 | 59,003 | ||||||
| Property, plant and equipment | 1,585 | 2,920 | 4,159 | 430 | 1,000 | 1,866 | 2,655 | ||
| Long-term investments and receivables | 2,000 | 2,000 | |||||||
| Accounts and financing receivable, after allowance for credit loss | 2,000 | 2,000 | |||||||
| Intangible assets, net (including goodwill) | 200,176 | 225,272 | 250,324 | ✕ | ✕ | ||||
| Intangible assets, net (excluding goodwill) | 200,176 | 225,272 | 250,324 | ||||||
| Other noncurrent assets | 1,209 | 2,247 | 1,160 | ✕ | |||||
| Assets held-for-sale, long lived | ✕ | ✕ | ✕ | ✕ | ✕ | 300 | |||
| Other undisclosed noncurrent assets | 177 | 35,224 | |||||||
| Total noncurrent assets: | 239,172 | 264,379 | 314,646 | 2,430 | 3,000 | 2,043 | 38,179 | ||
| TOTAL ASSETS: | 341,715 | 369,322 | 480,782 | 145,166 | 160,371 | 163,867 | 401,218 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 50,207 | 55,638 | 54,789 | 3,483 | 4,607 | 4,107 | 8,636 | ||
| Accounts payable | 6,012 | 13,800 | 17,609 | 1,656 | 1,943 | 2,609 | 6,121 | ||
| Accrued liabilities | 44,195 | 41,838 | 37,180 | 1,827 | 1,528 | 1,498 | 2,515 | ||
| Employee-related liabilities | 1,136 | ||||||||
| Debt | 73,677 | ||||||||
| Deferred compensation liability | 392 | 265 | |||||||
| Estimated litigation liability | 64,010 | ||||||||
| Deferred revenue and credits | ✕ | 456 | |||||||
| Other undisclosed current liabilities | 286,504 | 8,596 | (1,528) | (135) | 1,933 | ||||
| Total current liabilities: | 410,388 | 64,234 | 118,799 | 3,483 | 3,471 | 4,237 | 11,025 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 258,538 | 225,584 | |||||||
| Long-term debt, excluding current maturities | 258,538 | 225,584 | |||||||
| Liabilities, other than long-term debt | 796 | 596 | 612 | 342 | 388 | 1,846 | 1,875 | ||
| Liability for uncertainty in income taxes | 381 | 342 | 388 | 1,846 | 1,875 | ||||
| Other liabilities | 796 | 596 | 231 | ||||||
| Other undisclosed noncurrent liabilities | 19,391 | 31,016 | |||||||
| Total noncurrent liabilities: | 20,187 | 290,150 | 226,196 | 342 | 388 | 1,846 | 1,875 | ||
| Total liabilities: | 430,575 | 354,384 | 344,995 | 3,825 | 3,859 | 6,083 | 12,900 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | (88,860) | 14,938 | 135,787 | 141,341 | 156,512 | 157,784 | 388,318 | ||
| Common stock | 552,506 | 551,925 | 551,259 | 475,333 | 467,034 | 466,229 | 471,712 | ||
| Additional paid in capital | 79,295 | 73,185 | 69,149 | 97,377 | 97,838 | 95,844 | 296,024 | ||
| Accumulated other comprehensive income | 101,640 | 103,802 | 102,587 | 102,969 | 102,969 | 102,969 | 102,969 | ||
| Accumulated deficit | (822,301) | (713,974) | (587,208) | (534,338) | (511,329) | (507,258) | (482,387) | ||
| Total stockholders' equity: | (88,860) | 14,938 | 135,787 | 141,341 | 156,512 | 157,784 | 388,318 | ||
| TOTAL LIABILITIES AND EQUITY: | 341,715 | 369,322 | 480,782 | 145,166 | 160,371 | 163,867 | 401,218 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 130,432 | 138,438 | 13,574 | |||||
| Revenue, net | ✕ | 138,438 | 13,574 | |||||
| Cost of revenue | (59,697) | (77,220) | (5,971) | (1,121) | (154) | |||
| Cost of goods and services sold | (59,697) | (77,220) | (5,971) | |||||
| Gross profit: | 70,735 | 61,218 | 7,603 | (1,121) | (154) | |||
| Operating expenses | (120,802) | (148,016) | (44,309) | (25,411) | (31,338) | (27,369) | (54,521) | |
| Other undisclosed operating income | 2,066 | 27,509 | ||||||
| Operating loss: | (50,067) | (86,798) | (36,706) | (23,345) | (3,829) | (28,490) | (54,675) | |
| Nonoperating income (expense) | (1,830) | (292) | (1,999) | 358 | (368) | 3,251 | 8,511 | |
| Foreign currency transaction gain (loss), before tax | 32 | (62) | (32) | (8) | ||||
| Other nonoperating income (expense) | (1,830) | (292) | (1,999) | 49 | 115 | 207 | 60 | |
| Interest and debt expense | (4,333) | |||||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (13,700) | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (56,230) | (87,090) | (52,405) | (22,987) | (4,197) | (25,239) | (46,164) | |
| Other undisclosed loss from continuing operations before income taxes | (50,498) | (39,037) | ||||||
| Loss from continuing operations before income taxes: | (106,728) | (126,127) | (52,405) | (22,987) | (4,197) | (25,239) | (46,164) | |
| Income tax expense (benefit) | (1,599) | (583) | (465) | (22) | 192 | (599) | 3,900 | |
| Loss from continuing operations: | (108,327) | (126,710) | (52,870) | (23,009) | (4,005) | (25,838) | (42,264) | |
| Income (loss) from discontinued operations | (66) | 967 | 87,963 | |||||
| Net income (loss): | (108,327) | (126,710) | (52,870) | (23,009) | (4,071) | (24,871) | 45,699 | |
| Other undisclosed net loss attributable to parent | (1) | |||||||
| Net income (loss) available to common stockholders, diluted: | (108,327) | (126,710) | (52,870) | (23,009) | (4,071) | (24,871) | 45,698 | |
Comprehensive Income ($ in thousands)
| 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (108,327) | (126,710) | (52,870) | (23,009) | (4,071) | (24,871) | 45,699 | |
| Other comprehensive loss | (382) | |||||||
| Comprehensive income (loss): | (108,327) | (126,710) | (53,252) | (23,009) | (4,071) | (24,871) | 45,699 | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (2,162) | 1,215 | (1) | |||||
| Comprehensive income (loss), net of tax, attributable to parent: | (110,489) | (125,495) | (53,252) | (23,009) | (4,071) | (24,871) | 45,698 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.